GLOW peptide stack

GHK-Cu + BPC-157 + TB-500, usually sold as one pre-mixed injectable vial

GLOW is a marketing name for three injectable peptides sold in one vial. Nobody has studied the three together, in people or in animals.⁶ Each part has mostly animal data, and the one test of two of them together (BPC-157 with TB-500, in rats) found no added benefit.⁷ No licensed pharmacy can legally make the blend.

Ingredients

Each card shows the evidence for that peptide on its own, from its MoveWell guide.

Scale: 5 FDA-approved, 4 strong human, 3 limited human, 2 animal or lab only, 1 anecdotal. TB-500 is not thymosin β4 (Tβ4); human trials of full-length Tβ4 don't count toward its grade.⁸

What it's claimed to do

GLOW is marketed as a skin and repair stack: GHK-Cu for collagen and skin, plus BPC-157 and TB-500 as a "repair" pair for tendons, joints and wounds. The idea is that three mechanisms seen in lab and animal work add up. That has never been tested.

• Firmer, thicker skin and faster wound or scar healing
• Faster recovery from tendon, ligament and muscle injuries
• Hair, nails and general "anti-aging"

Doses and ratios vary by seller, so two "GLOW" vials may not contain the same thing.⁶

Evidence: the blend vs each part alone

The one combination test

In a 2026 rat Achilles tendon study (32 rats, four groups of eight), only TB-500 alone significantly improved tendon strength. The BPC-157 + TB-500 group improved one tissue score, but in their results the authors report that the combination "did not confer additional benefits compared to either agent alone."⁷ That test did not include GHK-Cu.

What's missing

• No study of GHK-Cu injected with anything, or of any injected GHK-Cu dose in people.
• No data on whether the three stay stable mixed in one vial. One newsletter raises pH and stability concerns but cites nothing.¹¹
• No human data on TB-500. FDA says TB-500 and thymosin β4 "are not the same substance" and found no study giving TB-500 to people.⁸ The human trials sometimes cited for it used full-length thymosin β4, and those efficacy trials mostly missed their primary endpoints.^{12, 13}

What users report

Risks and legal status

Risks

• Unknown contents. GLOW is sold only as a "research chemical". In August 2026 FDA warned five sellers that a "research use only" label doesn't excuse products clearly meant for people.¹⁸ A study of online semaglutide from unlicensed sellers reportedly found purity far below the label and one sample with high endotoxin (not re-verified by MoveWell);¹⁹ no such test of GLOW vials has been published.
• Immune reactions. FDA has said compounded injectable GHK-Cu and BPC-157 may cause immune reactions, made worse by aggregation and impurities.^{20, 10}
• Cancer questions. No study has tested TB-500 for cancer risk; FDA's written review noted the missing studies but raised no cancer finding.⁸ At the July 2026 meeting, FDA and several panelists reportedly discussed a potential cancer signal.²¹ FDA found no studies able to judge BPC-157's cancer risk.¹⁰
• Sport. BPC-157 (S0) and TB-500 (S2.3) are prohibited at all times under the WADA code.³
• Pregnancy, breastfeeding, active cancer, copper disorders. No data. Ask a clinician.

Legal status, part by part

Under the October 28, 2026 HHS policy, HHS won't act against licensed pharmacies that compound one of six peptides, one active ingredient per product, in set forms and routes. It is interim, not binding and not FDA approval.^{4, 22}

Injectable GHK-Cu goes to FDA's advisory committee by the end of February 2027. A vote alone would not create a legal path.²³

Safer or evidence-based alternatives

• For skin: topical GHK-Cu, which has a small randomized trial behind it (wrinkle volume down vs a plain serum at 8 weeks, n=40)²⁴ and a cosmetic safety review.²⁵ See our GHK-Cu guide for products that disclose their strength.
• For tendon pain: structured exercise. A network meta-analysis of 68 randomized trials found no convincing evidence that any add-on beat exercise alone for common leg tendinopathies, and recommends exercise first for at least 3 months.²⁶
• If you and a clinician still want to try one peptide: a single-ingredient BPC-157 or TB-500 product compounded by a licensed pharmacy with a prescription is the only route HHS has said it won't act against. That is enforcement discretion, not legal approval.⁴ Our BPC-157 vs TB-500 comparison sets out what each has behind it.

Where to get it

Single-ingredient options are covered in each guide: GHK-Cu (topical serums and compounded creams), BPC-157 and TB-500.

FAQ

References